MetaCap

RxSight (RXST) vs STAAR Surgical (STAA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

STAAR Surgical (STAA) has outperformed RxSight (RXST) over the past year, losing 13.5% versus a loss of 56.0%. Over five years, RXST leads with a -63.9% price change compared with -75.1% for STAA. STAAR Surgical is the larger company by market cap ($1.22 billion vs $187.4 million), about 6.5 times the size, while RxSight is growing revenue faster (-3.9% vs -23.7%).

RxSight converts more of its revenue into profit, with a net margin of -29.0% versus -33.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RXST-55.96%STAA-13.50%
+33%-13%-60%
Nov 21, 20251 yearNov 20, 2026
RXST-66.94%STAA-77.99%
+378%+135%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RXST versus STAA key metrics
MetricRXSTSTAA
Share price$4.47$24.22
Market cap$187.42M$1.22B
1-day change-3.04%-3.24%
YTD return-57.10%+4.89%
1-year return-55.96%-13.50%
5-year return-63.86%-75.08%
Forward P/E—21.39
EPS (TTM)$-1.29$0.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$134.48M$239.44M
Revenue growth (YoY)-3.89%-23.72%
Net income (latest FY)$-38.94M$-80.45M
Gross margin76.60%76.19%
Operating margin-35.84%-38.30%
Net margin-28.96%-33.60%
52-week high$13.22$35.87
52-week low$4.11$15.59
Distance from 52-week high-66.19%-32.48%
Analyst consensusholdbuy
Avg. price target upside+36.47%+17.92%
Average volume826.96K835.89K
Shares outstanding41.93M50.20M
Employees461921
SectorHealth CareHealth Care
IndustryOphthalmic GoodsOphthalmic Goods

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STAAR Surgical is about 6.5 times larger than RxSight by market value ($1.22B vs $187.42M).
  • STAA has outperformed RXST by 42.5 percentage points over the past year.
  • RxSight grew revenue faster in its latest fiscal year (-3.89% vs -23.72%).

About RxSight

RXST stock →

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Health Care · Ophthalmic Goods · 461 employees

About STAAR Surgical

STAA stock →

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

Health Care · Ophthalmic Goods · 921 employees

RXST vs STAA FAQ

Which is bigger, RxSight or STAAR Surgical?

STAAR Surgical (STAA) is larger, with a market capitalization of $1.22B compared with $187.42M for RxSight (RXST).

Which stock has performed better over the past year, RXST or STAA?

STAA returned -13.50% over the past 12 months, compared with -55.96% for RXST (price return, excluding dividends). Past performance does not predict future results.

Are RxSight and STAAR Surgical in the same industry?

Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.

More comparisons